Summary
Introduction
High-dose chemotherapy (HDCT) followed by autologous PBPC rescue as consolidation after conventionaldose salvage treatment may increase the response and survival rates in patients with relapsed or refractory GCT [1] . However, salvage treatment in intensively pretreated patients is highly toxic leading to severe hematologic toxicity as well as to neurotoxicity, hearing impairment and other organ toxicities [2] [3] [4] . These toxicities are relevant and may result in inferior clinical outcome as well as in impairment of the quality of life during and after treatment. Therefore, the availability of a cytoprotective agent would clearly be desirable.
Amifostine has been reported to protect normal tissues from radiation damage and to reduce the cytotoxic effects on normal cells of alkylating and platinum-based chemotherapy without compromising its anti-tumor effect [5] [6] [7] [8] [9] [10] . In order to determine the role of amifostine in protection from chemotherapy-induced toxicities in patients with cisplatin-pretreated GCT, we performed an open-label, prospective and randomized single center study.
Patients and methods

Patients
Forty patients were randomized either lo receive amifostine (group A. n -20) or no amifostine (group B, n -20). The randomization was stratified according to the number of prior cisplatin cycles (^ 6 vs > 6) in order to balance intensity of previous treatments between two study groups. All patients had received etoposide and 28 of 40 (70%) patients had received ifosfamide as part of their initial treatment Patient characteristics at study entry were well balanced between the two study arms (Table 1) . Group A patients with amifostine: group B -patients without amifostine. All differences were not statistically significant with P > 0.05 (Fisher's exact lest)
Treatment
Mobilization treatment with 175 mg/m 2 pachtaxel and 5 g/m 2 ifosfamide (Tl) followed by 10 ug/kg/day G-CSF (Filgrastim), conventionaldose treatment with 175 mg/m 2 paclitaxel. 5 x 1.2 g/m 2 ifosfamide and 5 x 20 mg/m 2 cisplatin followed by 5 ug/kg/day G-CSF and HDCTwith 3 x 500 mg/m 2 carboplatin, 4 x 600 mg/m 2 etoposide and 3 x 150 mg/m 2 thiotcpa (CET) plus 5 ug/kg/day G-CSF and PBPC rescue was administered as described before [11.12] . Irrespective of recipients' body surface area (median. 1.9 ITT: range, 1.4 to 2.4 m"), an absolute dose of 500 mg amifostine was given over 30 mm in 100 ml normal saline solution During TI amifostine was administered just before pachtaxel. During each TIP cycle amifostine was given before paclitaxel and daily prior to cisplatin. During CET patients received amifostine twice daily with the first dose before carboplatin and the second dose before etoposide. At the last day of HDCTonly a single dose of amifostine before etoposide was given.
Supportive care
Details of the HDCT and the supportive care have been previously reported [13] , Prophylactic measures included oral ciprofloxacin 3 x 250 mg per day and oral amphotencin B 2400 mg daily, both starting one day before HDCT and lasting until bone marrow recovered or temperatures exceeded. As soon as fever >38.0°C occurred oral ciprofloxacin was stopped and empiric intravenous antibiotic treatment was initiated with a combination of cefotaxime and piperacillin. In non-responders vancomycin was given with or without a switch to meropenem after 3 febrile days. Red blood cell and single-donor platelet transfusions were used lo maintain the hemoglobin level between 9 and 10 g/l and platelets > 10 x IO 9 /1. All blood products were leukodepleted and irradiated with 25 Gy before transfusion.
Definitions
Evaluations of toxicities were performed after each treatment cycle and classified according to modified criteria of the World Health Organization (WHO). Peripheral neurotoxicity (paresthesia, sensorymotor toxicity) and ototoxicity were classified -with minor modificationsaccording to the National Cancer Institute of Canada Expanded Common Toxicity Criteria. Paresthesia was considered grade 2 if it was mild and tolerable, grade 3 when paresthesia was prominent and disturbed daily activities and grade 4 if paresthesia became intolerable and required treatment. Sensorymotor toxicity was considered grade 2 if minor impairment of daily activities was noted, grade 3 if objective weakness and loss of function occurred that interfered with daily activities and grade 4 when loss of function required supportive measures. Ototoxicity was considered grade 2 if there was tinnitus or mild hearing impairment that did not interfere with daily activities, grade 3 if tinnitus or hearing impairment interfered with daily activities and grade 4 if a hearing aid was required.
All patients had a complete evaluation of their tumor status and toxicities at study entry, prior to high-dose CET, 6 and 12 weeks post HDCT. Thereafter, patients were re-evaluated every 3 months during the first year and every 6 months during subsequent years. A complete remission (CR) was present if there was disappearance of all radiologic manifestations and normalization of tumor markers. Patients with normalization of tumor markers, but radiologic evidence of disease were considered PRm-. Patients with a reduction of radiologic manifestations of 50% or more or with a decline of tumor markers of 90% or more were considered having a PRm+ All other patients were classified as having stable disease (SD) or progressive disease (PD).
Statistical analysis
Calculations were performed using the PRISM statistical software (GraphPad Software Inc., San Diego, California). The Mann-Whitney U-test was used for comparisons of continuous variables between the study groups Categorical variables were compared using Fisher's exact test Differences with a P-value less than 0.05 were considered statistically significant. Based on observations by Rick et al. [12] , the study was planned to accrue 40 patients. At a significance level of onetailed P < 0.05 (alpha-error), this sample size provided greater than 80% power to detect a 30% reduction in the incidence of overall severe neurotoxicity
Results
Conventional-dose chemotherapy with TIP was discontinued in seven patients. One cycle of TIP was administered to one single patient of group A and to another patient of group B. Two treatment cycles were administered to two patients of group A and to three patients of group B. In eight patients further study treatment with HDCT was discontinued because of progressive tumor (n -3), severe complications during TIP including osteomyelitis (n = 1), encephalopathy (n = 1), death due to septic shock (n = 1) and patient refusal (n -2). Therefore, HDCT with CET was administered to 17 of 20 (85%) patients of group A and to 15 of 20 (75%) patients of group B.
All patients were evaluable for toxicity after conventional dose treatment with TIP and 32 of 40 (80%) patients could be analyzed for toxicity after high-dose CET.
Myelosuppression and hematopoietic reconstitution
After conventional-dose treatment with TIP there were no statistically significant differences between group A and group B in respect to grade 4 leukocytopenia, anemia or thrombocytopenia (Table 2) . After TIP the total transfusion requirements in each arm were compa- Table 2 . Maximal toxicities during conventional-doseTIP and after HDCTwith CET in patients with (A) or without (B) amifostine. (7) 3 (21) S (56) 1 (7) 3 (21) 10 ( Abbreviations. WHO -world health organisation. Entry -evaluation prior to initiation of salvage treatment: TIP -taxol/ifosfamide/cisplatin. HDCT -high-dose chemotherapy, CET -carboplatin/etoposide/thiotepa; wks -weeks after autologous stem cell rescue; WBC -white blood cells; PUT -platelets; Hb, hemoglobin, group A -patients with amifostine; group B -patients without amifostine " All differences were not statistically significant with P > 0.05 (Fisher's exact test )). Furthermore, the median days of fever (1 day (range 0 to 7 days) of group A vs. 3 days (range 0 to 10 days) of group B) were also comparable between both study arms. One patient of group B died after the third cycle of TIP because of neutropenic fever followed by a septic shock syndrome. Likewise, the time intervals between treatment cycles during conventional-dose treatment with TIP were comparable between the two study arms. The median time interval from the first treatment day of the previous chemotherapy cycle until the subsequent cycle was 22 days in both groups after the first TIP cycle, 22 days in group A vs. 23 days in group B after the second TIP cycle, and 23 days in group A vs. 27 days in group B after the third TIP cycle. No patient required dose reductions due to excess hematologic toxicity.
After HDCT all patients of group A and group B developed grade 4 hematologic toxicity and were reinfused with autologous PBPC using comparable median doses of CD34+ cells/kg (3.4 x 10 6 (range 2.5 to 9.7) vs. 3.8 x 10 6 (range 1.3 to 52.8)) and colony-forming units granulocyte-macrophage/kg (17.6 x 10 4 (range 5.2 to 105.5) vs. 18.7 x 10 4 (range 5.9 to 71.6)) in patients of group A and group B, respectively. Following PBPC rescue hematopoietic reconstitution as defined by neutrophils > 0.5 x 1O Treatment with TIP had to be discontinued because of severe paresthesia after the second cycle of TIP in two patients of group A and in one patient of group B. These latter three patients immediately received full dose CET. Ototoxicity greater than grade 2 had to be observed in no patient of group A, but in 2 of 20 (10%) patients of group B.
In both study groups peripheral neuropathy and hearing impairment significantly worsened with subsequent HDCT after TIP. No statistically significant differences could be observed overall between patients of group A and group B in terms of overall grade 2-4 paresthesia, sensorymotor or hearing impairments. However, no patient of group A who received additional amifostine suffered from grade 4 paresthesia or sensorymotor impairment, whereas these side-effects occurred in 2 of 15 (14%) patients of group B. Possibly due to the small number of patients this observation was not statistically significant (P = 0.21). Peripheral neurotoxicity and hearing impairment after HDCT persisted in most patients during the 12 week re-evaluation period and improved only gradually thereafter (Table 2 ).
Other to.xicities
Mild to moderate nephrotoxicity occurred during conventional-dose TIP (Table 2) . Renal impairment required a dose reduction of CET in 3 of 17 (17%) patients of group A and 3 of 15 (20%) patients of group B. Nevertheless, three patients of group B needed hemodialysis whereas this was not required in any patient of group A. Two patients died from treatment related multiorgan failure on day +5 and +16 after PBPC rescue: one patient of group A and another patient of group B, respectively. Further severe complications occurred only in group B patients: one patient developed osteomyelitis during conventional-dose TIP and another patient encephalopathy grade 3 after high-dose CET. All other toxicities like mucositis, nausea, transient elevation of liver enzymes and skin toxicity occurred as expected throughout the study treatment and particularly after HDCT, but were fully reversible in all patients during the followup period after completion of the study treatment. Known side-effects of amifostine such as hypotension and emesis did not become apparent in patients of group A neither during conventional-dose TIP nor during high-dose CET.
Responses
A favorable response (CR, PRm-or PRm+) was obtained in 15 of 17 (85%) patients of group A and in 13 of 15 (86%) patients of group B. Overall, the best response after HDCT with CET was a CR in 8 of 32 (25%) patients, 17 of 32 (54%) patients achieved a PRm-and 3 of 32 (9%) had a PRm+ lasting for two and three months. The remaining 2 of 32 (6%) patients had PD and two patients (6%) died from multiorgan toxicity after HDCT. The median follow-up time was 18 months (range 5 to 32 months). Among group A and group B, 12 of 20 (60%) patients and 14 of 20 (70%) patients had relapsed.
Discussion
The present study confirmed feasability and tolerability of i.v. administration of amifostine plus intensive combination chemotherapy. In none of the patients, amifostine had to be discontinued. With respect to the reduction of chemotherapy-related toxicities after conventional-dose TIP or after high-dose CET, we could not observe any statistically significant differences between patients treated with and without amifostine. Yet, in patients who received amifostine together with TIP particularly severe hematologic toxicities grade 4 were less common. After TIP as well as after HDCT severe neurotoxicities grade 3 to 4 and severe nephrotoxicity ^ grade 2 also seemed to be less frequent in patients who received amifostine as compared to those who did not. Furthermore, no differences were observed in respect to supportive care requirements and hematopoietic reconstitution after PBPC in patients treated with and without amifostine. Likewise, the response rates after TIP and highdose CET as well as the event-free and overall survival rates were comparable between the two study arms. So far, no data exist for the administration of amifostine during HDCT with autologous PBPC rescue. Gelmon et al. treated 40 patients suffering from metastatic breast cancer with dose-escalated paclitaxel. Twenty patients were randomized to additionally receive amifostine [14] . The authors found no advantage for amifostine in respect to hematologic toxicity or neurotoxicity. However, the small number of patients and the administration of paclitaxel as a single agent with a low overall incidence of side-effects, limit the interpretation of that study. In contrast, two recent randomized trials demonstrated an advantage for the combination of amifostine with chemotherapy in comparison with chemotherapy alone [6, 9] . Kemp et al. analyzed a large study population and included only previously untreated patients. It is conceivable that a chemoprotective effect of amifostine might vary in different clinicial scenarios and that more subtile effects will only become apparent in large clinical trials. In another study patients with various solid tumors were randomized to receive carboplatin either alone or in combination with amifostine prior and after the administration of carboplatin infusions [9] . Patients in the treatment arm that included amifostine showed significantly smaller decreases in their platelet counts. However, the clinical relevance of this observation is questionable because the median platelet values (127 x 10 9 /l platelets in patients with amifostine vs. 88 x 10 9 /l platelets in patients without amifostine) never reached a critical level. As the non-hematologic toxicities of carboplatin monotherapy were low no additional protective effect of amifostine treatment could be detected.
In comparison with these previous studies our present trial had several advantages. First, our study was a prospective randomized phase III trial investigating amifostine in an intensively pretreated study population with a high risk for treatment-related toxicity [12] . Second, for an effective salvage treatment we had to administer a highly toxic regimen with a reasonable potential to demonstrate a possible effect of amifostine. Third, an absolute dose of 500 mg amifostine was low, but the cumulative doses of amifostine used in our study were higher than the cumulative amifostine doses administered in other studies. We decided to give a fixed dose of 500 mg amifostine once daily during conventional-dose chemotherapy and twice daily throughout HDCT. The reasons for this decision were the higher practicability of a repeated administration and the unclear data concerning the optimal dose of amifostine when the study was initiated in 1995. Until then, no data had existed for the combination of amifostine with highdose chemotherapy in patients with GCT. Furthermore, at study entry no results from pharmacological trials were available comparing a single mega-dosing of amifostine with a serial low-dose application. The small number of patients, the discontinuation of TIP in several patients, the low number of patients who received HDCT and the repeated low-dose application of amifostine are major limitations of the present study and could be explain why no significant differences were found. Therefore, the immediate benefits in the present trial were small.
However, our data demonstrate that the addition of amifostine to the conventional-dose TIP and/or highdose CET as salvage treatment in GCT may have a cytoprotective effect and might reduce the incidence of severe neurotoxicity and, possibly, also myelotoxicity.
